Biphosphonate Therapy, Risk of Fracture, and Sites of Bone Mineral Density Assessments in Kidney Transplantation
- PMID: 30910935
- PMCID: PMC6493988
- DOI: 10.1681/ASN.2019010079
Biphosphonate Therapy, Risk of Fracture, and Sites of Bone Mineral Density Assessments in Kidney Transplantation
Keywords: kidney transplantation; mineral metabolism; renal osteodystrophy.
Comment in
-
Authors' Reply.J Am Soc Nephrol. 2019 May;30(5):906. doi: 10.1681/ASN.2019020124. Epub 2019 Mar 25. J Am Soc Nephrol. 2019. PMID: 30910936 Free PMC article. No abstract available.
Comment on
-
A Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year after Kidney Transplantation.J Am Soc Nephrol. 2019 Feb;30(2):355-365. doi: 10.1681/ASN.2018060656. Epub 2019 Jan 3. J Am Soc Nephrol. 2019. PMID: 30606784 Free PMC article. Clinical Trial.
References
-
- Segaud N, Legroux I, Hazzan M, Noel C, Cortet B: Changes in bone mineral density after kidney transplantation: 2-Year assessment of a French cohort. Osteoporos Int 29: 1165–1175, 2018 - PubMed
-
- Hansen D, Olesen JB, Gislason GH, Abrahamsen B, Hommel K: Risk of fracture in adults on renal replacement therapy: A Danish national cohort study. Nephrol Dial Transplant 31: 1654–1662, 2016 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
